How synaptic signaling proteins shape brain circuits and behavior
Regulation of in vivo cortical circuit function and behavior by synaptic GEFs and GAPs
Researchers are exploring how changes in two brain proteins (Trio and SYNGAP1) alter nerve-cell connections and behavior to help people with neurodevelopmental disorders.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11418331 on NIH RePORTER |
What this research studies
This center studies how the genes Trio and Syngap1 control the wiring and function of different cortical neuron types using detailed laboratory experiments. Scientists use three classes of mouse models that change gene expression, introduce point mutations, or alter timing of expression to see effects across molecular, cellular, synaptic, circuit, and behavioral levels. Methods include two-photon microscopy, biochemical and cellular assays, and behavioral tests to link gene changes to decision-making and adaptive behavior. The work aims to map how specific gene defects lead to circuit dysfunctions associated with neurodevelopmental disorders.
Who could benefit from this research
Good fit: People with neurodevelopmental disorders caused by or linked to Trio or SYNGAP1 genetic changes, and families interested in research on these specific genetic forms of NDDs, would be most relevant.
Not a fit: Patients without Trio- or SYNGAP1-related conditions or those seeking immediate clinical treatment are unlikely to receive direct benefit from this basic-science center.
Why it matters
Potential benefit: If successful, this research could reveal how Trio and SYNGAP1 changes disrupt brain circuits and point toward targets for future therapies or clinical trials for related neurodevelopmental disorders.
How similar studies have performed: Prior mouse and molecular studies show that SYNGAP1 and Trio influence synapse function and behavior, but translating these findings into human therapies remains at an early preclinical stage.
Where this research is happening
Chicago, United States
- Northwestern University — Chicago, United States (Active)
Researchers
- Principal investigator: Rumbaugh, Gavin R — Northwestern University
- Study coordinator: Rumbaugh, Gavin R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.